LOCAL

"Toronto Woman Fights for Coverage of $80K Cancer Drug"

19.11.2026 2,44 B 5 Mins Read

A Toronto woman, Holly Wardlow, is battling to obtain coverage for her nearly $80,000 per month cancer treatment from the province after facing two rejections. Wardlow, a professor at the University of Toronto, was diagnosed with cholangiocarcinoma, a rare and aggressive cancer of the bile ducts, in March of the previous year after she began experiencing health issues.

“For me, that means I have a tumor inside my liver,” Wardlow shared. To address her tumor, she initially underwent chemotherapy and immunotherapy, which are the standard treatments for her type of cancer. Although these methods resulted in some shrinkage of the tumor, it was not sufficient to allow for either surgical removal or a liver transplant.

During her treatment, her oncologist introduced her to zenocutuzumab, a targeted therapy specifically designed to attack the mutation in her tumor that fuels its growth. “It’s basically a molecule or chemical that targets the mutation on my tumor that is making it grow,” explained Wardlow. This treatment is distinct from traditional chemotherapy, as it is designed to selectively target cancer cells without affecting healthy cells.

Since beginning treatment with zenocutuzumab in mid-April, Wardlow has reported significant tumor shrinkage, which she feels has markedly improved her quality of life. “This really has not just prolonged my life so far, but also really restored my health so that I can do things like visit family more often and go on hiking trips with my stepdaughter,” she stated.

Despite the positive effects of the treatment, the financial burden is immense. The drug, which is only available in the United States, costs approximately $39,000 Canadian per dose, with Wardlow requiring two doses each month, accumulating to about $78,000 monthly. “We’ve used up all of our savings,” Wardlow shared, noting the financial strain on her family. To cope with the costs, they initiated a GoFundMe campaign and received assistance from her parents and brother, who even paid for one of her doses.

Wardlow's attempt to have the treatment funded through Cancer Care Ontario’s case-by-case review program, which helps patients with rare and life-threatening conditions, has been denied twice. The responses indicated that the drug is not eligible for funding as it is still undergoing clinical trials in the U.S., which are expected to conclude by the end of 2026. Furthermore, zenocutuzumab has not yet passed a funding review in Canada.

The Ministry of Health has not commented on Wardlow's specific situation due to patient confidentiality. However, they clarified that Health Canada is responsible for authorizing drug use in Canada and noted that zenocutuzumab has not been submitted for market approval in the country. Partner Therapeutics, the company that manufactures the drug, stated that they do not currently plan to file a formal submission for full approval in Canada, although they are providing support for individual patient access globally.

With the aid of her GoFundMe campaign and assistance from her family, Wardlow anticipates having enough funds for two doses in December. Currently, she is awaiting the outcome of her appeal of her application to the provincial review program, though she remains uncertain about when a decision will be made.

Related Post